Fujirebio
Fujirebio Europe to Distribute Self-Screen Cervical Cancer Test
The test is designed to detect elevated methylation levels of cervical cancer biomarkers and may be used as a triage follow-up test of HPV-positive women.
Fujirebio Europe, Ohmx.bio Nab $873K Grant to Develop Clinical Third-Generation Sequencing Platform
The firms said that they will initially focus on the development of a portable, modular platform to detect highly polymorphic regions.
Morphotek, Fujirebio to Develop CA125 II Assay as CDx
The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.
4,000-plus Patient Study Suggests ROCA Test Specific Enough for Use as Ovarian Cancer Screening Dx
Premium
A longitudinal study of the Risk of Ovarian Cancer Algorithm has found that the algorithm in combination with transvaginal ultrasound offers suitable specificity and positive predictive value for it to be used as an ovarian cancer screening test in post-menopausal women.